Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C17H25N3O5S.3H2O |
| Molecular Weight | 437.508 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 6 / 6 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O.O.O.C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(S[C@@H]3CN[C@@H](C3)C(=O)N(C)C)=C(N2C1=O)C(O)=O
InChI
InChIKey=CTUAQTBUVLKNDJ-OBZXMJSBSA-N
InChI=1S/C17H25N3O5S.3H2O/c1-7-12-11(8(2)21)16(23)20(12)13(17(24)25)14(7)26-9-5-10(18-6-9)15(22)19(3)4;;;/h7-12,18,21H,5-6H2,1-4H3,(H,24,25);3*1H2/t7-,8-,9+,10+,11-,12-;;;/m1.../s1
| Molecular Formula | C17H25N3O5S |
| Molecular Weight | 383.463 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 6 / 6 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
| Molecular Formula | H2O |
| Molecular Weight | 18.0153 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionSources: https://web.archive.org/web/20161209014344/http://www.ds-pharma.com:80/rd/new_value/meropen.htmlCurator's Comment: description was created based on several sources, including
http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050706s036lbl.pdf |
Sources: https://web.archive.org/web/20161209014344/http://www.ds-pharma.com:80/rd/new_value/meropen.html
Curator's Comment: description was created based on several sources, including
http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050706s036lbl.pdf |
Meropenem (generic name: meropenem hydrate) is a carbapenem antibiotic for injection showing a strong antibacterial activity to a wide range of bacteria strains from Gram-positive bacteria, Gram-negative bacteria to anaerobic bacteria. It is used as single agent therapy for the treatment of the following infections: complicated skin and skin structure infections due to Staphylococcus aureus (b-lactamase and non-b-lactamase producing, methicillin-susceptible isolates only), Streptococcus pyogenes, Streptococcus agalactiae, viridans group streptococci. This drug also used in case of Intra-abdominal Infections for the treatment complicated appendicitis and peritonitis caused by viridans group streptococci, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Bacteroides fragilis, B. thetaiotaomicron, and Peptostreptococcus species. In addition is used the treatment of bacterial meningitis caused by Streptococcus pneumoniae, Haemophilus influenzae (b-lactamase and non-b-lactamase-producing isolates), and Neisseria meningitides. The bactericidal activity of meropenem results from the inhibition of cell wall synthesis. Meropenem readily penetrates the cell wall of most Gram-positive and Gram-negative bacteria to reach penicillin-binding-protein (PBP) targets. Its strongest affinities are toward PBPs 2, 3 and 4 of Escherichia coli and Pseudomonas aeruginosa; and PBPs 1, 2 and 4 of Staphylococcus aureus. Meropenem has significant stability to hydrolysis by β-lactamases, both penicillinases and cephalosporinases produced by Gram-positive and Gram-negative bacteria. Meropenem should not be used to treat methicillin-resistant Staphylococcus aureus (MRSA) or methicillin-resistant Staphylococcus epidermidis (MRSE). Meropenem product with such superior effectiveness and safety has been approved for marketing by 100 countries or more in the world (as of March 2004) since its first launch in Italy in 1994.
CNS Activity
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2354204 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Curative | MERREM Approved UseTo reduce the development of drug-resistant bacteria and maintain the effectiveness of Meropenem for injection, USP (I.V.) and other antibacterial drugs, Meropenem for injection, USP (I.V.) should only be used to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Meropenem for injection, USP (I.V.) is useful as presumptive therapy in the indicated condition (e.g. intra-abdominal infections) prior to the identification of the causative organisms because of its broad spectrum of bactericidal activity. For information regarding use in pediatric patients see Indications and Usage (1.1), (1.2) or (1.3); Dosage and Administration (2.3), Adverse Reactions (6.1), and Clinical Pharmacology (12.3). Meropenem for injection (I.V.) is a penem antibacterial indicated as single agent therapy for the treatment of: Complicated skin and skin structure infections (adult patients and pediatric patients 3 months of age and older only). (1.1) Complicated intra-abdominal infections (adult and pediatric patients). (1.2) Bacterial meningitis (pediatric patients 3 months of age and older only). (1.3) To reduce the development of drug-resistant bacteria and maintain the effectiveness of Meropenem for injection (I.V.) and other antibacterial drugs, Meropenem for injection (I.V.) should only be used to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. 1.1 Skin and Skin Structure Infections (Adult Patients and Pediatric Patients 3 Months of age and older only) Meropenem for injection, USP (I.V.) is indicated as a single agent therapy for the treatment of complicated skin and skin structure infections due to Staphylococcus aureus (methicillin-susceptible isolates only), Streptococcus pyogenes, Streptococcus agalactiae, viridans group streptococci, Enterococcus faecalis (vancomycin-susceptible isolates only), Pseudomonas aeruginosa, Escherichia coli, Proteus mirabilis, Bacteroides fragilis, and Peptostreptococcus species. 1.2 Intra-abdominal Infections (Adult and Pediatric Patients) Meropenem for injection, USP (I.V.) is indicated as a single agent therapy for the treatment of complicated appendicitis and peritonitis caused by viridans group streptococci, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Bacteroides fragilis, B. thetaiotaomicron, and Peptostreptococcus species. 1.3 Bacterial Meningitis (Pediatric Patients 3 Months of age and older only) Meropenem for injection, USP (I.V.) is indicated as a single agent therapy for the treatment of bacterial meningitis caused by Streptococcus pneumoniae ‡, Haemophilus influenzae, and Neisseria meningitidis. ‡ The efficacy of meropenem as monotherapy in the treatment of meningitis caused by penicillin nonsusceptible isolates of Streptococcus pneumoniae has not been established. Meropenem for injection, USP (I.V.) has been found to be effective in eliminating concurrent bacteremia in association with bacterial meningitis., 1.1 Skin and Skin Structure Infections (Adult Patients and Pediatric Patients 3 Months of age and older only) Meropenem for injection, USP (I.V.) is indicated as a single agent therapy for the treatment of complicated skin and skin structure infections due to Staphylococcus aureus (methicillin-susceptible isolates only), Streptococcus pyogenes, Streptococcus agalactiae, viridans group streptococci, Enterococcus faecalis (vancomycin-susceptible isolates only), Pseudomonas aeruginosa, Escherichia coli, Proteus mirabilis, Bacteroides fragilis, and Peptostreptococcus species., 1.2 Intra-abdominal Infections (Adult and Pediatric Patients) Meropenem for injection, USP (I.V.) is indicated as a single agent therapy for the treatment of complicated appendicitis and peritonitis caused by viridans group streptococci, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Bacteroides fragilis, B. thetaiotaomicron, and Peptostreptococcus species., 1.3 Bacterial Meningitis (Pediatric Patients 3 Months of age and older only) Meropenem for injection, USP (I.V.) is indicated as a single agent therapy for the treatment of bacterial meningitis caused by Streptococcus pneumoniae ‡, Haemophilus influenzae, and Neisseria meningitidis. ‡ The efficacy of meropenem as monotherapy in the treatment of meningitis caused by penicillin nonsusceptible isolates of Streptococcus pneumoniae has not been established. Meropenem for injection, USP (I.V.) has been found to be effective in eliminating concurrent bacteremia in association with bacterial meningitis. Launch Date1996 |
|||
| Primary | MERREM Approved UseTo reduce the development of drug-resistant bacteria and maintain the effectiveness of Meropenem for injection, USP (I.V.) and other antibacterial drugs, Meropenem for injection, USP (I.V.) should only be used to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Meropenem for injection, USP (I.V.) is useful as presumptive therapy in the indicated condition (e.g. intra-abdominal infections) prior to the identification of the causative organisms because of its broad spectrum of bactericidal activity. For information regarding use in pediatric patients see Indications and Usage (1.1), (1.2) or (1.3); Dosage and Administration (2.3), Adverse Reactions (6.1), and Clinical Pharmacology (12.3). Meropenem for injection (I.V.) is a penem antibacterial indicated as single agent therapy for the treatment of: Complicated skin and skin structure infections (adult patients and pediatric patients 3 months of age and older only). (1.1) Complicated intra-abdominal infections (adult and pediatric patients). (1.2) Bacterial meningitis (pediatric patients 3 months of age and older only). (1.3) To reduce the development of drug-resistant bacteria and maintain the effectiveness of Meropenem for injection (I.V.) and other antibacterial drugs, Meropenem for injection (I.V.) should only be used to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. 1.1 Skin and Skin Structure Infections (Adult Patients and Pediatric Patients 3 Months of age and older only) Meropenem for injection, USP (I.V.) is indicated as a single agent therapy for the treatment of complicated skin and skin structure infections due to Staphylococcus aureus (methicillin-susceptible isolates only), Streptococcus pyogenes, Streptococcus agalactiae, viridans group streptococci, Enterococcus faecalis (vancomycin-susceptible isolates only), Pseudomonas aeruginosa, Escherichia coli, Proteus mirabilis, Bacteroides fragilis, and Peptostreptococcus species. 1.2 Intra-abdominal Infections (Adult and Pediatric Patients) Meropenem for injection, USP (I.V.) is indicated as a single agent therapy for the treatment of complicated appendicitis and peritonitis caused by viridans group streptococci, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Bacteroides fragilis, B. thetaiotaomicron, and Peptostreptococcus species. 1.3 Bacterial Meningitis (Pediatric Patients 3 Months of age and older only) Meropenem for injection, USP (I.V.) is indicated as a single agent therapy for the treatment of bacterial meningitis caused by Streptococcus pneumoniae ‡, Haemophilus influenzae, and Neisseria meningitidis. ‡ The efficacy of meropenem as monotherapy in the treatment of meningitis caused by penicillin nonsusceptible isolates of Streptococcus pneumoniae has not been established. Meropenem for injection, USP (I.V.) has been found to be effective in eliminating concurrent bacteremia in association with bacterial meningitis., 1.1 Skin and Skin Structure Infections (Adult Patients and Pediatric Patients 3 Months of age and older only) Meropenem for injection, USP (I.V.) is indicated as a single agent therapy for the treatment of complicated skin and skin structure infections due to Staphylococcus aureus (methicillin-susceptible isolates only), Streptococcus pyogenes, Streptococcus agalactiae, viridans group streptococci, Enterococcus faecalis (vancomycin-susceptible isolates only), Pseudomonas aeruginosa, Escherichia coli, Proteus mirabilis, Bacteroides fragilis, and Peptostreptococcus species., 1.2 Intra-abdominal Infections (Adult and Pediatric Patients) Meropenem for injection, USP (I.V.) is indicated as a single agent therapy for the treatment of complicated appendicitis and peritonitis caused by viridans group streptococci, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Bacteroides fragilis, B. thetaiotaomicron, and Peptostreptococcus species., 1.3 Bacterial Meningitis (Pediatric Patients 3 Months of age and older only) Meropenem for injection, USP (I.V.) is indicated as a single agent therapy for the treatment of bacterial meningitis caused by Streptococcus pneumoniae ‡, Haemophilus influenzae, and Neisseria meningitidis. ‡ The efficacy of meropenem as monotherapy in the treatment of meningitis caused by penicillin nonsusceptible isolates of Streptococcus pneumoniae has not been established. Meropenem for injection, USP (I.V.) has been found to be effective in eliminating concurrent bacteremia in association with bacterial meningitis. Launch Date1996 |
|||
| Curative | MERREM Approved UseTo reduce the development of drug-resistant bacteria and maintain the effectiveness of Meropenem for injection, USP (I.V.) and other antibacterial drugs, Meropenem for injection, USP (I.V.) should only be used to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Meropenem for injection, USP (I.V.) is useful as presumptive therapy in the indicated condition (e.g. intra-abdominal infections) prior to the identification of the causative organisms because of its broad spectrum of bactericidal activity. For information regarding use in pediatric patients see Indications and Usage (1.1), (1.2) or (1.3); Dosage and Administration (2.3), Adverse Reactions (6.1), and Clinical Pharmacology (12.3). Meropenem for injection (I.V.) is a penem antibacterial indicated as single agent therapy for the treatment of: Complicated skin and skin structure infections (adult patients and pediatric patients 3 months of age and older only). (1.1) Complicated intra-abdominal infections (adult and pediatric patients). (1.2) Bacterial meningitis (pediatric patients 3 months of age and older only). (1.3) To reduce the development of drug-resistant bacteria and maintain the effectiveness of Meropenem for injection (I.V.) and other antibacterial drugs, Meropenem for injection (I.V.) should only be used to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. 1.1 Skin and Skin Structure Infections (Adult Patients and Pediatric Patients 3 Months of age and older only) Meropenem for injection, USP (I.V.) is indicated as a single agent therapy for the treatment of complicated skin and skin structure infections due to Staphylococcus aureus (methicillin-susceptible isolates only), Streptococcus pyogenes, Streptococcus agalactiae, viridans group streptococci, Enterococcus faecalis (vancomycin-susceptible isolates only), Pseudomonas aeruginosa, Escherichia coli, Proteus mirabilis, Bacteroides fragilis, and Peptostreptococcus species. 1.2 Intra-abdominal Infections (Adult and Pediatric Patients) Meropenem for injection, USP (I.V.) is indicated as a single agent therapy for the treatment of complicated appendicitis and peritonitis caused by viridans group streptococci, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Bacteroides fragilis, B. thetaiotaomicron, and Peptostreptococcus species. 1.3 Bacterial Meningitis (Pediatric Patients 3 Months of age and older only) Meropenem for injection, USP (I.V.) is indicated as a single agent therapy for the treatment of bacterial meningitis caused by Streptococcus pneumoniae ‡, Haemophilus influenzae, and Neisseria meningitidis. ‡ The efficacy of meropenem as monotherapy in the treatment of meningitis caused by penicillin nonsusceptible isolates of Streptococcus pneumoniae has not been established. Meropenem for injection, USP (I.V.) has been found to be effective in eliminating concurrent bacteremia in association with bacterial meningitis., 1.1 Skin and Skin Structure Infections (Adult Patients and Pediatric Patients 3 Months of age and older only) Meropenem for injection, USP (I.V.) is indicated as a single agent therapy for the treatment of complicated skin and skin structure infections due to Staphylococcus aureus (methicillin-susceptible isolates only), Streptococcus pyogenes, Streptococcus agalactiae, viridans group streptococci, Enterococcus faecalis (vancomycin-susceptible isolates only), Pseudomonas aeruginosa, Escherichia coli, Proteus mirabilis, Bacteroides fragilis, and Peptostreptococcus species., 1.2 Intra-abdominal Infections (Adult and Pediatric Patients) Meropenem for injection, USP (I.V.) is indicated as a single agent therapy for the treatment of complicated appendicitis and peritonitis caused by viridans group streptococci, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Bacteroides fragilis, B. thetaiotaomicron, and Peptostreptococcus species., 1.3 Bacterial Meningitis (Pediatric Patients 3 Months of age and older only) Meropenem for injection, USP (I.V.) is indicated as a single agent therapy for the treatment of bacterial meningitis caused by Streptococcus pneumoniae ‡, Haemophilus influenzae, and Neisseria meningitidis. ‡ The efficacy of meropenem as monotherapy in the treatment of meningitis caused by penicillin nonsusceptible isolates of Streptococcus pneumoniae has not been established. Meropenem for injection, USP (I.V.) has been found to be effective in eliminating concurrent bacteremia in association with bacterial meningitis. Launch Date1996 |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
44.9 μg/mL |
20 mg/kg 3 times / day other, intravenous dose: 20 mg/kg route of administration: Intravenous experiment type: OTHER co-administered: |
MEROPENEM unknown | Homo sapiens population: UNHEALTHY age: NEWBORN sex: UNKNOWN food status: UNKNOWN |
|
61 μg/mL |
30 mg/kg 3 times / day other, intravenous dose: 30 mg/kg route of administration: Intravenous experiment type: OTHER co-administered: |
MEROPENEM unknown | Homo sapiens population: UNHEALTHY age: NEWBORN sex: UNKNOWN food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
445 μg × h/mL |
20 mg/kg 3 times / day other, intravenous dose: 20 mg/kg route of administration: Intravenous experiment type: OTHER co-administered: |
MEROPENEM unknown | Homo sapiens population: UNHEALTHY age: NEWBORN sex: UNKNOWN food status: UNKNOWN |
|
444 μg × h/mL |
30 mg/kg 3 times / day other, intravenous dose: 30 mg/kg route of administration: Intravenous experiment type: OTHER co-administered: |
MEROPENEM unknown | Homo sapiens population: UNHEALTHY age: NEWBORN sex: UNKNOWN food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
2.33 h |
20 mg/kg 3 times / day other, intravenous dose: 20 mg/kg route of administration: Intravenous experiment type: OTHER co-administered: |
MEROPENEM unknown | Homo sapiens population: UNHEALTHY age: NEWBORN sex: UNKNOWN food status: UNKNOWN |
|
1.58 h |
30 mg/kg 3 times / day other, intravenous dose: 30 mg/kg route of administration: Intravenous experiment type: OTHER co-administered: |
MEROPENEM unknown | Homo sapiens population: UNHEALTHY age: NEWBORN sex: UNKNOWN food status: UNKNOWN |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Antibiotic-resistant gram-negative organisms in pediatric chronic-care facilities. | 2002-03-15 |
|
| Antibiotic resistance among clinical isolates of Acinetobacter in the UK, and in vitro evaluation of tigecycline (GAR-936). | 2002-03 |
|
| Use of Etests with carbapenems for Gram-negative rods producing beta-lactamases. | 2002-02 |
|
| Pharmacokinetics and pharmacodynamics of meropenem in critically ill patients. | 2002-02 |
|
| Carbapenem-resistant Acinetobacter and role of curtains in an outbreak in intensive care units. | 2002-02 |
|
| In vitro activity of the aerosolized agents colistin and tobramycin and five intravenous agents against Pseudomonas aeruginosa isolated from cystic fibrosis patients in southwestern Germany. | 2002-02 |
|
| Meropenem stability to beta-lactamase hydrolysis and comparative in vitro activity against several beta-lactamase-producing Gram-negative strains. | 2002-02 |
|
| Comparative in vitro activity of isepamicin and other antibiotics against gram-negative bacilli from intensive care units (ICU) in Belgium. | 2002-01-05 |
|
| Acute necrotizing gastritis by Escherichia coli in a severely neutropenic patient. | 2002-01 |
|
| Antimicrobial susceptibilities among clinical isolates of extended-spectrum cephalosporin-resistant Gram-negative bacteria in a Taiwanese University Hospital. | 2002-01 |
|
| Primary liver abscess caused by one clone of Klebsiella pneumoniae with two colonial morphotypes and resistotypes. | 2002-01 |
|
| [The high level resistance to carbapenems in Acinetobacter baumannii is a multifactorial problem]. | 2001-12-19 |
|
| A novel metallo-beta-lactamase, Mbl1b, produced by the environmental bacterium Caulobacter crescentus. | 2001-12-14 |
|
| [Activity of new fluoroquinolones against clinical isolates of Acinetobacter baumannii]. | 2001-12 |
|
| Antimicrobial susceptibility of respiratory isolates of Enterobacteriaceae and Staphylococcus aureus in Italy: incidence and trends over the period 1997-1999. | 2001-12 |
|
| Empirical monotherapy with meropenem in serious bacterial infections in children. | 2001-12 |
|
| Comparative in-vitro activity of carbapenem antibiotics against respiratory pathogens isolated between 1999 and 2000. | 2001-12 |
|
| Survey of antibiotic resistance in Pseudomonas aeruginosa by The Tokyo Johoku Association of Pseudomonas Studies. | 2001-12 |
|
| Meropenem pharmacokinetics in children and adolescents receiving hemodialysis. | 2001-12 |
|
| Unit differences in pathogen occurrence arising from the MYSTIC program European database (1997-2000). | 2001-12 |
|
| MYSTIC program: summary of European data from 1997 to 2000. | 2001-12 |
|
| Antimicrobial resistance trends in medical centers using carbapenems: report of 1999 and 2000 results from the MYSTIC program (USA). | 2001-12 |
|
| Determining the value of antimicrobial surveillance programs. | 2001-12 |
|
| MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) conference. Hamburg, Germany, 10 May 2001. | 2001-12 |
|
| In-vitro activities of various antibiotics, alone and in combination with amikacin against Pseudomonas aeruginosa. | 2001-12 |
|
| National shortages of antimicrobial agents: results of 2 surveys from the Infectious Diseases Society of America Emerging Infections Network. | 2001-11-01 |
|
| [A case of eosinophilic pneumonia possibly due to ifenprodil]. | 2001-11 |
|
| [Comparative antibacterial activity of carbapenems against P. aeruginosa (1)]. | 2001-11 |
|
| Spectrum and activity of three contemporary fluoroquinolones tested against Pseudomonas aeruginosa isolates from urinary tract infections in the SENTRY Antimicrobial Surveillance Program (Europe and the Americas; 2000): more alike than different! | 2001-11 |
|
| In vitro and in vivo activities of meropenem and comparable antimicrobial agents against Haemophilus influenzae, including beta-lactamase-negative ampicillin-resistant strains. | 2001-11 |
|
| Influence of in-vivo endotoxin liberation on anti-anaerobic antimicrobial efficacy. | 2001-10 |
|
| Failure of cefotaxime and meropenem to eradicate meningitis caused by an intermediately susceptible Streptococcus pneumoniae strain. | 2001-10 |
|
| Effects of cefepime and meropenem on the gastrointestinal colonization of surgical patients by Candida albicans. | 2001-09-19 |
|
| Synthesis and biological properties of new 1beta-methylcarbapenems containing heteroaromatic thioether moiety. | 2001-09-03 |
|
| [A randomized, controlled clinical trial of meropenem and imipenem/cilastatin in the treatment of acute bacterial infections]. | 2001-09 |
|
| [Susceptibility to penicillin and 13 antimicrobial agents in erythromycin-resistant viridans group streptococci isolated from blood cultures]. | 2001-09 |
|
| [Pyogenic sacroiliitis in pregnancy]. | 2001-09 |
|
| [Antimicrobial activities of carbapenems and fourth generation cephems against clinically isolated strains]. | 2001-09 |
|
| Frequency of isolation and antimicrobial resistance of gram-negative and gram-positive bacteria from patients in intensive care units of 25 European university hospitals participating in the European arm of the SENTRY Antimicrobial Surveillance Program 1997-1998. | 2001-09 |
|
| Effect of meropenem on disposition kinetics of valproate and its metabolites in rabbits. | 2001-09 |
|
| Isolation and culture of airway epithelial cells from chronically infected human lungs. | 2001-09 |
|
| Characterization of paired mucoid/non-mucoid Pseudomonas aeruginosa isolates from Danish cystic fibrosis patients: antibiotic resistance, beta-lactamase activity and RiboPrinting. | 2001-09 |
|
| [Antimicrobial activities and mechanisms of carbapenem resistance in clinical isolates of carbapenem-resistant Pseudomonas aeruginosa and Acinetobacter spp]. | 2001-08 |
|
| Use of broad spectrum antibiotics in six non-university Swiss hospitals. | 2001-07-28 |
|
| [In vitro and in vivo activities of panipenem against penicillin-resistant Streptococcus pneumoniae]. | 2001-07 |
|
| Ertapenem: a new carbapenem. | 2001-06 |
|
| Antibiotic persistence: the role of spontaneous DNA repair response. | 2001 |
|
| Investigation of synergism of meropenem and ciprofloxacin against Pseudomonas aeruginosa and Acinetobacter strains isolated from intensive care unit infections. | 2001 |
|
| Piperacillin/tazobactam: a pharmacoeconomic review of its use in moderate to severe bacterial infections. | 2001 |
|
| [Antibiotic therapy of cystic fibrosis in children]. | 2001 |
Sample Use Guides
Adult Patients: The recommended dose of MERREM I.V. is 500 mg given every 8 hours for skin and skin structure infections and 1 gram given every 8 hours for intra-abdominal infections. When treating complicated skin and skin structure infections caused by P.aeruginosa, a dose of 1 gram every 8 hours is recommended.
Pediatric Patients 3 Months of Age and Older: For pediatric patients 3 months of age and older, the MERREM I.V. dose is 10 mg/kg, 20 mg/kg or 40 mg/kg every 8 hours (maximum dose is 2 grams every 8 hours), depending on the type of infection (complicated skin and skin structure, intra-abdominal or meningitis). Pediatric patients weighing over 50 kg should be administered MERREM I.V. at a dose of 500 mg every 8 hours for complicated skin and skin structure infections, 1 gram every 8 hours for intra-abdominal infections and 2 grams every 8 hours for meningitis. MERREM I.V. should be given as intravenous infusion over approximately 15 minutes to 30 minutes or as an intravenous bolus injection (5 mL to 20 mL) over approximately 3 minutes to 5 minutes. There is limited safety data available to support the administration of a 40 mg/kg (up to a maximum of 2 grams) bolus dose.
Route of Administration:
Intravenous
In Vitro Use Guide
Curator's Comment: Meropenem was 4-64 times more active than imipenem against gram-negatives, including Enterobacteriaceae organisms, Pseudomonas aeruginosa, Burkholderia cepacia, Neisseria meningiditis, and Haemophilus influenzae. Imipenem was up to 2-4 times more active than meropenem against some gram-positive cocci, including Enterococcus faecalis. Meropenem, unlike imipenem or ceftazidime, was bactericidal for all strains of Enterobacteriaceae, P. aeruginosa, and gram-positive cocci tested at < or = 8 times the MIC.
Unknown
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:23:28 GMT 2025
by
admin
on
Mon Mar 31 18:23:28 GMT 2025
|
| Record UNII |
FV9J3JU8B1
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WHO-VATC |
QJ01DH02
Created by
admin on Mon Mar 31 18:23:28 GMT 2025 , Edited by admin on Mon Mar 31 18:23:28 GMT 2025
|
||
|
NCI_THESAURUS |
C260
Created by
admin on Mon Mar 31 18:23:28 GMT 2025 , Edited by admin on Mon Mar 31 18:23:28 GMT 2025
|
||
|
NDF-RT |
N0000175496
Created by
admin on Mon Mar 31 18:23:28 GMT 2025 , Edited by admin on Mon Mar 31 18:23:28 GMT 2025
|
||
|
WHO-ATC |
J01DH02
Created by
admin on Mon Mar 31 18:23:28 GMT 2025 , Edited by admin on Mon Mar 31 18:23:28 GMT 2025
|
||
|
WHO-ATC |
J01DH52
Created by
admin on Mon Mar 31 18:23:28 GMT 2025 , Edited by admin on Mon Mar 31 18:23:28 GMT 2025
|
||
|
FDA ORPHAN DRUG |
130799
Created by
admin on Mon Mar 31 18:23:28 GMT 2025 , Edited by admin on Mon Mar 31 18:23:28 GMT 2025
|
||
|
LIVERTOX |
NBK547861
Created by
admin on Mon Mar 31 18:23:28 GMT 2025 , Edited by admin on Mon Mar 31 18:23:28 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
441129
Created by
admin on Mon Mar 31 18:23:28 GMT 2025 , Edited by admin on Mon Mar 31 18:23:28 GMT 2025
|
PRIMARY | |||
|
DB00760
Created by
admin on Mon Mar 31 18:23:28 GMT 2025 , Edited by admin on Mon Mar 31 18:23:28 GMT 2025
|
PRIMARY | |||
|
MEROPENEM
Created by
admin on Mon Mar 31 18:23:28 GMT 2025 , Edited by admin on Mon Mar 31 18:23:28 GMT 2025
|
PRIMARY | |||
|
Meropenem
Created by
admin on Mon Mar 31 18:23:28 GMT 2025 , Edited by admin on Mon Mar 31 18:23:28 GMT 2025
|
PRIMARY | |||
|
CHEMBL127
Created by
admin on Mon Mar 31 18:23:28 GMT 2025 , Edited by admin on Mon Mar 31 18:23:28 GMT 2025
|
PRIMARY | |||
|
BB-52
Created by
admin on Mon Mar 31 18:23:28 GMT 2025 , Edited by admin on Mon Mar 31 18:23:28 GMT 2025
|
PRIMARY | |||
|
FV9J3JU8B1
Created by
admin on Mon Mar 31 18:23:28 GMT 2025 , Edited by admin on Mon Mar 31 18:23:28 GMT 2025
|
PRIMARY | |||
|
1392454
Created by
admin on Mon Mar 31 18:23:28 GMT 2025 , Edited by admin on Mon Mar 31 18:23:28 GMT 2025
|
PRIMARY | |||
|
m7240
Created by
admin on Mon Mar 31 18:23:28 GMT 2025 , Edited by admin on Mon Mar 31 18:23:28 GMT 2025
|
PRIMARY | Merck Index | ||
|
SUB21617
Created by
admin on Mon Mar 31 18:23:28 GMT 2025 , Edited by admin on Mon Mar 31 18:23:28 GMT 2025
|
PRIMARY | |||
|
DTXSID10274179
Created by
admin on Mon Mar 31 18:23:28 GMT 2025 , Edited by admin on Mon Mar 31 18:23:28 GMT 2025
|
PRIMARY | |||
|
C059500
Created by
admin on Mon Mar 31 18:23:28 GMT 2025 , Edited by admin on Mon Mar 31 18:23:28 GMT 2025
|
PRIMARY | |||
|
FV9J3JU8B1
Created by
admin on Mon Mar 31 18:23:28 GMT 2025 , Edited by admin on Mon Mar 31 18:23:28 GMT 2025
|
PRIMARY | |||
|
759621
Created by
admin on Mon Mar 31 18:23:28 GMT 2025 , Edited by admin on Mon Mar 31 18:23:28 GMT 2025
|
PRIMARY | |||
|
6770
Created by
admin on Mon Mar 31 18:23:28 GMT 2025 , Edited by admin on Mon Mar 31 18:23:28 GMT 2025
|
PRIMARY | |||
|
1709
Created by
admin on Mon Mar 31 18:23:28 GMT 2025 , Edited by admin on Mon Mar 31 18:23:28 GMT 2025
|
PRIMARY | |||
|
100000085626
Created by
admin on Mon Mar 31 18:23:28 GMT 2025 , Edited by admin on Mon Mar 31 18:23:28 GMT 2025
|
PRIMARY | |||
|
29561
Created by
admin on Mon Mar 31 18:23:28 GMT 2025 , Edited by admin on Mon Mar 31 18:23:28 GMT 2025
|
PRIMARY | RxNorm | ||
|
43968
Created by
admin on Mon Mar 31 18:23:28 GMT 2025 , Edited by admin on Mon Mar 31 18:23:28 GMT 2025
|
PRIMARY | |||
|
C1160
Created by
admin on Mon Mar 31 18:23:28 GMT 2025 , Edited by admin on Mon Mar 31 18:23:28 GMT 2025
|
PRIMARY | |||
|
119478-56-7
Created by
admin on Mon Mar 31 18:23:28 GMT 2025 , Edited by admin on Mon Mar 31 18:23:28 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
BINDER->LIGAND |
BINDING
|
||
|
TRANSPORTER -> SUBSTRATE | |||
|
ANHYDROUS->SOLVATE | |||
|
EXCRETED UNCHANGED |
Meropenem: approximately 40–60% of dose was excreted unchanged within 24 to 48 hours with a further 28% recovered as the microbiologically inactive hydrolysis product; fecal elimination accounts for ~2% of dose.
|
||
|
|
PARENT -> SALT/SOLVATE | |||
|
TRANSPORTER -> SUBSTRATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
IMPURITY -> PARENT |
correction factor: for the calculation of content, multiply the peak area of impurity A by 1.6
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
| Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
|---|---|---|---|---|---|---|
| Volume of Distribution | PHARMACOKINETIC |
|
|
|||
| Biological Half-life | PHARMACOKINETIC |
|
|
|||